Hepatitis A vaccination by intracutaneous low dose administration: A less expensive alternative

被引:10
作者
Carlsson, U
Brudin, L
Eliasson, I
Hansson, BG
机构
[1] KALMAR HOSP,DEPT CLIN PHYSIOL,S-39185 KALMAR,SWEDEN
[2] KALMAR HOSP,DEPT MICROBIOL,S-39185 KALMAR,SWEDEN
[3] LUND UNIV,MALMO GEN HOSP,DEPT MED MICROBIOL,S-21401 MALMO,SWEDEN
关键词
D O I
10.3109/00365549609037934
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We investigated the immune response to three different intracutaneous (i.c.) doses of inactivated hepatitis A vaccine: 72, 144, and 216 ELISA units (EU). The response was measured using a quotient score derived from a Commercial enzyme-linked immunosorbent assay (HAVAB Abbott) and translated to IU per liter using a World Health Organization standard serum for hepatitis A virus antibody, The results were compared with the results obtained after an intramuscular (i.m.) full dose, i.e. 1,440 EU, at 0 and 6-12 months. As estimated from antibody concentration, 3 lots of 144 EU i.c. with 100% or two lots of 216 EU i.c. with 98% seroconversion results in at least as goad early protection as the standard immunization with one lot of 1,440 EU i.m., (79% with our method), Indeed, only two doses of 144 EU vaccine (90% seroconversion) seem to give results comparable to the standard procedure. After the booster dose the median antibody concentration is 1,290 IU/I for the 144 EU vaccine and 837 for the 216 EU one, compared with an antibody response of 990 IU/I for the standard 1,440 EU i.m, vaccination. In conclusion, three doses of 144 EU vaccine i.c, or, as an alternative, two doses of 216 EU at monthly intervals give good early protection (e.g, before travel). After the booster dose, which is given 6 months to I year later, the serological response is comparable to the standard procedure of two doses of the 1,440 EU vaccine given i.m. and with 100% seroconversion in all three programs.
引用
收藏
页码:435 / 438
页数:4
相关论文
共 7 条
[1]   WHO SHOULD RECEIVE HEPATITIS-A VACCINE - CONSIDERATIONS FOR THE DEVELOPMENT OF AN IMMUNIZATION STRATEGY [J].
MARGOLIS, HS ;
SHAPIRO, CN .
VACCINE, 1992, 10 :S85-S87
[2]   ALL THESE POSITIVE TESTS TO THIMEROSAL [J].
MOLLER, H .
CONTACT DERMATITIS, 1994, 31 (04) :209-213
[3]   INTRAMUSCULAR VERSUS INTRADERMAL ADMINISTRATION OF A RECOMBINANT HEPATITIS-B VACCINE - A COMPARISON OF RESPONSE RATES AND ANALYSIS OF FACTORS INFLUENCING THE ANTIBODY-RESPONSE [J].
STRUVE, J ;
ARONSSON, B ;
FRENNING, B ;
GRANATH, F ;
VONSYDOW, M ;
WEILAND, O .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1992, 24 (04) :423-429
[4]   INACTIVATED HEPATITIS-A VACCINE - REACTOGENICITY, IMMUNOGENICITY, AND LONG-TERM ANTIBODY PERSISTENCE [J].
VANDAMME, P ;
THOELEN, S ;
CRAMM, M ;
DEGROOTE, K ;
SAFARY, A ;
MEHEUS, A .
JOURNAL OF MEDICAL VIROLOGY, 1994, 44 (04) :446-451
[5]   HEPATITIS-A VACCINE - A NEW CONVENIENT SINGLE-DOSE SCHEDULE WITH BOOSTER WHEN LONG-TERM IMMUNIZATION IS WARRANTED [J].
VICTOR, J ;
KNUDSEN, JD ;
NIELSEN, LP ;
FOMSGAARD, A ;
THYBO, S ;
BYGBJERG, I ;
WESTH, H .
VACCINE, 1994, 12 (14) :1327-1329
[6]  
VRANCKX R, 1994, JAMA-J AM MED ASSOC, P494
[7]   INTRADERMAL, SUBCUTANEOUS OR INTRAMUSCULAR ADMINISTRATION OF HEPATITIS-B VACCINE - SIDE-EFFECTS AND ANTIBODY-RESPONSE [J].
WAHL, M ;
HERMODSSON, S .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1987, 19 (06) :617-621